Abstract:Background/Objectives: Primary biliary cholangitis (PBC) is an autoimmune chronic cholestatic disease of the liver that symptomatically can present with pruritus and fatigue. Its established first- and second-line therapies are ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) although they provide limited symptom management. Liver transplantation offers a potentially curative therapeutic option in refractory cases progressing to cirrhosis. Novel research published after the current guidelines highlights the importance of providing an up-to-date analysis of treatment options available. Methods: In this study, we conducted a literature search using Pubmed, Ovid Medline, and SCOPUS to provide a narrative review of first-line, second-line, and emerging therapies in PBC. Results: UDCA has been well established as a long-term, safe therapy within the literature although it is possible that treatment dosage can be further optimised in refractory patients. It has a favourable side effect profile. Despite improving biochemical markers, histopathological profile, and overall outcomes, up to 30–40% of patients are refractory to it. Age and sex are highlighted as independent indicators of non-responsiveness. This necessitates effective second-line therapies. Future trials could aim to investigate UDCA as a co-first-line therapy. Further supporting results for OCA were found in the interim extension trial of the seminal POISE study. The long-term phase 4 COBOLT trial is still awaiting results to further assess the complications, adherence, and potential adverse effects. It is a viable option in UDCA-refractory patients. The high incidence rate of dose-related pruritis indicates that alternative second-line options are needed. Bezafibrate is an off-label antilipemic agent that shows promise as a prospective second-line therapy option. The landmark BEZURSO trial alleviated some efficacy and safety concerns, but it remains associated with elevated serum creatinine; thus, it should be considered with caution. Other prospective second-line therapies are budesonide, triple therapy, and novel agents such as seladelpar and elafibranor. Conclusions: UDCA should remain the treatment of choice for PBC, though perhaps not as monotherapy. With further investigation, BF shows promise as a new second-line therapy alongside OCA, which it may outperform.

Pharmacotherapy for primary biliary cholangitis: an assessment of medication candidacy and rates of treatment

Obeticholic Acid—A Pharmacological and Clinical Review

Up-to-Date Snapshot of Current and Emerging Medical Therapies in Primary Biliary Cholangitis

Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid

New Therapies for Primary Biliary Cirrhosis

Primary biliary cholangitis: pathogenesis and therapeutic opportunities

Response to Ursodeoxycholic Acid May Be Assessed Earlier to Allow Second-Line Therapy in Patients with Unresponsive Primary Biliary Cholangitis

Obeticholic acid for the treatment of primary biliary cirrhosis

Advances in the Treatment of Primary Biliary Cholangitis

Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators

Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Therapy Landscape

Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics

Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials.

[Primary biliary cholangitis-response criteria of first-line treatment and perspectives of second-line therapy]

Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion

Novel therapeutic targets in primary biliary cirrhosis

Primary Biliary Cholangitis and Incomplete Response to Ursodeoxycholic Acid Therapy: Who is Guilty and What to Do?

Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study

Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis

Ursodeoxycholic Acid at 18–22 Mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis

Revisiting PPAR agonists: novel perspectives in the treatment of primary biliary cholangitis